Salute e Benessere
Daphne NeuroCare™: A Breakthrough Personalized Protocol for Neurodivergent Care in Children and Adults
PRESS RELEASE
Introducing Daphne NeuroCare™: the integrated protocol revolutionizing the treatment of neurodivergent conditions in children and adults
A new frontier in the treatment of neurodivergent conditions is taking shape with Daphne NeuroCare™, the innovative clinical protocol developed by the international Daphne Lab®, pioneers for over 25 years in the field of bioenergetic medicine and advanced metadiagnostics.
The project, born from the synergy between clinical neuroscience and integrative medicine, offers a personalized and multidisciplinary approach to conditions such as ADHD, Asperger’s syndrome, and autism spectrum disorder (ASD). Leading the initiative is an international team of physicians, biologists, psychologists, nutritionists, and pediatricians, under the scientific supervision of Dr. Luigi Di Vaia, founder of Daphne Lab® and a key figure in bioenergetic medicine.
Unlike traditional therapeutic models that rely primarily on behavioral and pharmacological assessments, Daphne NeuroCare™ is based on an in-depth and measurable analysis of each patient’s biochemical, neurological, and epigenetic markers. The protocol is grounded in third-generation BioMetaTests®, exclusive diagnostic tools capable of detecting nutritional intolerances, intestinal dysbiosis, oxidative stress, neurotransmitter imbalances, and more.
“This is not just a therapeutic scheme,” explains Dr. Di Vaia, “but a
dynamic system of neuro-nutritional modulation, able to adapt in real time to the unique biochemical profile of each individual.” The protocol consists of personalized clinical pathways built upon advanced nutraceutical integration, targeted adaptogenic support, and systemic regulation of the main neuroendocrine axes.
Initial clinical outcomes are highly encouraging: a multicenter study group active in the Balkans — in collaboration with accredited clinics in Albania, Kosovo, North Macedonia, and Montenegro — has documented significant clinical improvements in 70–85% of treated patients, depending on the type of condition and compliance with the protocol. In Albania, in particular, a partnership with Vip Health International and a local team trained directly by Daphne Lab® enabled the implementation of a replicable, effective, and safe therapeutic model.
Documented cases include non-verbal children who have started speaking, ADHD patients showing improvement in academic performance and emotional stability, and Asperger adolescents developing stronger relational skills. These results will soon be published in a peer-reviewed scientific article, complete with data, charts, and explanatory tables.
Daphne NeuroCare™ is not available for general use; it is exclusively administered by certified and authorized healthcare professionals trained in the clinical application of Daphne® multitests. This ensures high standards of safety, therapeutic efficacy, and protection against misuse or misinterpretation of the technologies involved.
With its international focus and a growing impact in the Balkan region, Daphne NeuroCare™ is set to become a benchmark in bioenergetic medicine applied to neuropsychological disorders — helping to shape a future that is more inclusive, conscious, and scientifically advanced in the care of neurodivergent individuals.
For further information:
Daphne Lab® Press Office
Email: info@daphnelab.com
Website: www.daphnelab.com